Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
Residential and Outpatient Schizophrenia Patients' Sleep Health Varies.
Read Full NewsThe 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
1.
Adjuvant Tx May Boost Survival in Bilateral Breast Cancer
2.
Lower screening age calls for more tailored bowel cancer surveillance
3.
Study identifies new approach to protect the brain during radiation therapy
4.
Research exposes far-reaching toll of financial hardship on patients with cancer
5.
Q&A: Breast cancer facts that could save lives
1.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
2.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
3.
Clinical Pharmacology of Erythropoiesis-Stimulating Pathway Modulators
4.
Exploring New Treatment Strategies for Mantle Cell Lymphoma
5.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the causes of anemia in adults beyond nutritional deficiencies
2.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge